Dianthus Therapeutics (DNTH) is a pre-revenue clinical-stage biotech with no product sales, no inventory, no PP&E of consequence, and no debt. The liquidation recovery posture is straightforwardly cash-dominant: total assets of $1.25B are comprised almost entirely of cash, cash equivalents, and investment securities. Under the liquidation lens, applying 100% recovery to cash and equivalents ($628M) and near-100% to investment securities ($597M amortized cost, $597M fair value with minor unrealized loss), gross recoverable assets approximate $1.22-1.24B before any haircut. Against total liabilities of only $45.6M—consisting of $38.3M current (primarily $31.1M accrued liabilities and $5.3M accounts payable) and $7.3M noncurrent (operating lease obligations $1.0M noncurrent, deferred revenue $6.3M noncurrent)—the equity recovery is substantially positive at roughly $1.20B book, consistent with MFFAIS's reported CLV/LLV of approximately $588-590M. The MFFAIS figure is materially lower than book equity ($1.20B) primarily because the CLV methodology applies haircuts to the investment securities portfolio and excludes intangible/pipeline value entirely, while also marking down non-cash assets. The dominant balance-sheet event this quarter is the March 2026 public offering raising gross proceeds of $719M at $81/share, which caused cash and investments to surge from a materially lower base. The $576M net increase in cash and equivalents for Q1 2026 is almost entirely financing-driven. On the liability side, the $30M already paid to Leads under the DNTH212 license agreement flowed through R&D expense in prior periods; the remaining contingent obligation of $8M (Phase 1 initiation milestone) and up to $962M in success-contingent milestones do not appear as balance sheet liabilities and will not crystallize absent specific clinical/regulatory triggers. Operating cash burn was $28.9M for Q1 2026, annualizing to approximately $115M. At the current burn rate, the $1.2B cash and investments position provides runway well into 2030 per management's own disclosure. Deferred revenue of $7.8M total ($1.5M current, $6.3M noncurrent) represents a recognized liability that would remain face-value in wind-down. Accumulated deficit reached $377.6M. No debt, no pension, no goodwill, no significant intangibles on-balance-sheet. The Zenas/Tenacia investment ($0.4M fair value) is immaterial. PP&E is $274K net—functionally zero in a liquidation context. The primary recovery risk is operating cash consumption against the liquid asset pool.
▼ Community Notes